Content uploaded by Zhixiang He
Author content
All content in this area was uploaded by Zhixiang He on Jul 07, 2021
Content may be subject to copyright.
Subscriber access provided by CORNELL UNIVERSITY LIBRARY
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Article Selective Degradation of GSPT1 by Cereblon Modulators
Identified via a Focused Combinatorial Library
Chelsea E. Powell, Guangyan Du, Jianwei Che, Zhixiang He, Katherine A Donovan, Hong
Yue, Eric S Wang, Rados#aw P. Nowak, Tinghu Zhang, Eric S Fischer, and Nathanael S Gray
ACS Chem. Biol., Just Accepted Manuscript • DOI: 10.1021/acschembio.0c00520 • Publication Date (Web): 31 Aug 2020
Downloaded from pubs.acs.org on September 1, 2020
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
1
Selective Degradation of GSPT1 by Cereblon
Modulators Identified via a Focused Combinatorial
Library
Chelsea E. Powell,‡ Guangyan Du, ‡ Jianwei Che, Zhixiang He, Katherine A. Donovan, Hong Yue,
Eric S. Wang, Radosław P. Nowak, Tinghu Zhang, Eric S. Fischer, Nathanael S. Gray*
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States
Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston,
Massachusetts 02115, United States
ABSTRACT
Cereblon (CRBN) is an E3 ligase adapter protein that can be reprogrammed by imide-class
compounds such as thalidomide, lenalidomide, and pomalidomide to induce the degradation of
neo-substrate proteins. In order to identify additional small molecule CRBN modulators, we
implemented a focused combinatorial library approach where we fused an imide-based CRBN
binding pharmacophore to a heterocyclic scaffold which could be further elaborated. We screened
the library for CRBN-dependent antiproliferative activity in the multiple myeloma cell line MM1.S
and identified five hit compounds. Quantitative chemical proteomics of hit compounds revealed
that they induced selective degradation of GSPT1, a translation termination factor that is currently
being explored as a therapeutic target for the treatment of acute myeloid leukemia. Molecular
Page 1 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2
docking studies with CRBN and GSPT1 followed by analog synthesis identified a possible
hydrogen bond interaction with the central pyrimidine ring as a molecular determinant of hit
compounds’ selectivity. This study demonstrates that focused combinatorial library design,
phenotypic screening, and chemical proteomics can provide a suitable workflow to efficiently
identify novel CRBN modulators.
INTRODUCTION
During the late 1950s and early 1960s thalidomide was sold as a sedative that was frequently
prescribed to pregnant women. Infamously, thalidomide use during pregnancy had teratogenic
activity, leading to birth defects such as limb, ear, cardiac, and gastrointestinal malformations.1 In
the following decades thalidomide was demonstrated to have immunomodulatory, anti-
inflammatory, and anti-angiogenic properties, which reignited interest in its therapeutic potential.2
This led to thalidomide being granted its first FDA approval in 1998 for the treatment of erythema
nodosum leprosum (ENL), a life-threatening inflammatory complication of lepromatous leprosy.2
Shortly afterwards thalidomide was shown to be an effective treatment for multiple myeloma,
resulting in the development of more potent immunomodulatory drugs (IMiDs) with lower
toxicities, including lenalidomide and pomalidomide as novel therapeutics to treat multiple
myeloma.2–4
Thalidomide’s molecular mechanism of action was found to depend on its ability to bind to the
adapter protein cereblon (CRBN), a substrate receptor component of the large E3 ubiquitin ligase
complex CUL4-RBX1-DDB1-CRBN (CRL4CRBN).1,5–7 Thalidomide directs the activity of CRBN
towards neo-substrates, leading to their ubiquitination and subsequent proteasomal degradation.
IMiDs and other compounds with similar mechanisms of action are frequently referred to as
“molecular glues” due to their ability to mediate interactions between two proteins that have not
Page 2 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3
evolved to interact and have no measurable binding affinity in the absence of a molecular glue
compound. The antiproliferative effects seen in multiple myeloma cells depend primarily on the
ability of thalidomide to induce the degradation of the zinc finger transcription factors Ikaros
(IKZF1) and Aiolos (IKZF3) which are regulators of hematopoietic lineage, while the teratogenic
activity appears to depend on its ability to degrade SALL4, a zinc finger protein which is essential
for limb development.8–10 Structural biology studies have revealed that all known IMiD-dependent
CRL4CRBN neo-substrates contain a conserved beta-hairpin motif which acts as a structural degron
that is recruited to a pocket in CRBN by imide-based compounds.11,12 In addition to zinc finger
proteins, some imide-based compounds can also induce the degradation of other proteins, such as
casein kinase 1A1 (CK1a), which is degraded by lenalidomide, and translation termination factor
G1 to S phase transition protein 1 (GSPT1), degraded by CC-885.12,13
These findings have stimulated tremendous interest in discovering new small molecules that can
direct CRBN to recruit substrates for degradation. The most popular strategy currently involves
the development of heterobifunctional small molecules frequently called PROTACs (PROteolysis
Targeting Chimeras) where a CRBN binding motif is tethered via a linker to a recruiting element
for a new target of interest.14–16 A second approach includes thalidomide-analogs as CRBN
modulators (molecular glues) that can recruit neo-substrates to the CRBN E3 ubiquitin ligase
complex.17,18 Both PROTACs and molecular glues have the ability to exhibit differentiated
pharmacology relative to traditional occupancy-based inhibitors due to their ability to degrade
proteins.19 An advantage of PROTACs is that they can be targeted towards distinct proteins by
basing their design on known binding ligands, whereas glues and their targets have been
discovered serendipitously or through phenotypic screening.18 Although clinical stage PROTACs
Page 3 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4
have been developed,19,20 it is challenging to obtain desirable drug-like properties due to their
typically higher molecular weight relative to glue-type molecules.
Figure 1. Workflow for identifying new CRBN modulators.
Here we develop a structured workflow for the identification, optimization, and validation of
CRBN modulators. Our approach uses a focused combinatorial analog library, designed based on
the fusion of heterocyclic scaffolds to an imide-based CRBN binding pharmacophore. We
screened this library for antiproliferative activity in the multiple myeloma cell line MM1.S (wild-
type (WT) and CRBN knockout). Compounds with CRBN-dependent antiproliferative activity
Page 4 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5
were selected for expression proteomics in order to identify degraded proteins (Figure 1). Through
this workflow we identified five hits from a library of 51 compounds. These five new CRBN
modulators were all shown to induce selective degradation of GSPT1. We used molecular docking
to rationalize the selectivity profile of hit compounds. We identified and validated a specific
hydrogen bond as a possible determinant of selectivity.
RESULTS AND DISCUSSION
IMiDs have shown the ability to drug targets traditionally considered to be “undruggable” due
to not possessing a small molecule binding pocket, such as IKZF1/3 and GSPT1. A literature
survey revealed that introducing small motifs (like -NH2, urea, or aniline) into the IMiD scaffold
can have a major impact on protein-protein complementarity between CRBN and the target neo-
substrate, resulting in differentiated neo-substrate selectivity. Inspired by these insights, we
designed a focused combinatorial library by replacing one chloro group in dichloroheterocyclic
scaffolds (including substituted pyrimidine and purine) with a lenalidomide moiety. The remaining
chloro group is then derivatized with a nucleophilic SNAr or palladium-mediated coupling reaction
with different anilines, alkyl amines and boronic acids/esters, which introduce various interactions
with potential target proteins. We explored two different pyrimidine scaffolds (scaffolds A and B),
where one is directly attached to lenalidomide (scaffold B) and the other has a short linkage in the
middle which covers more chemical and conformational space (scaffold A) (Table 1).
Additionally, we explored a purine scaffold directly attached to lenalidomide (scaffold C).
Page 5 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6
Table 1. IC50 (µM) values of thalidomide analogs.a
Page 6 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7
aCell viability in MM1.S WT and CRBN-/- cells after 48 h treatment (3 biological replicates). NA = no
activity. IC50s of 2, 26, and 29 shown as average of 2 separate runs (3 biological replicates each).
The majority of the 51 compounds in the library exhibited no antiproliferative activity in either
MM1.S WT or CRBN-/- up to a concentration of 20 µM. Seven compounds (8, 25, 36, 42, 43, 44,
and 47) had notable to slight antiproliferative activity in both cell lines (Table 1, Supplementary
Figure S1). This indicated that these compounds have CRBN-independent cytotoxicity. We
identified five hit compounds with strong CRBN-dependent antiproliferative activity: 2, 26, 29,
45, and 51. The five hit compounds all share a similar hydrophobic moiety even though they do
not belong to a single scaffold: compounds 2, 26, and 51 share the exact same 2,3-dihydro-1H-
inden-5-amine; 45 contains a similar 5,6,7,8- tetrahydronaphthalen-2-amine moiety, and 29 has a
trimethylaniline. The similarity of hydrophobic features suggested that these compounds could
recruit the same neo-substrate(s).
Page 7 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8
Figure 2. Hit compounds from CRBN-dependent antiproliferative activity screening and their degradative
activity of known CRBN modulator targets. (A) Structures of hit compounds. (B) in vitro TR-FRET CRBN
binding assay. (C) Cellular CRBN engagement assay. (D) Immunoblots after 4 h treatments in MM1.S
cells. Vinculin representative of 4 blots. Quantification shown as percentage of DMSO control normalized
to vinculin. CC-885, a CRBN modulator that induces GSPT1 degradation, is shown for comparison.12
Page 8 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9
Figure 3. Expression proteomics in MM1.S cells after 6 h treatment with compound or DMSO. (A)
Duplicate analysis of CC-885 (0.1 µM). (B) Triplicate analysis of 29 (1 µM). (C) Singlicate analysis of 2
(1 µM). (D) Singlicate analysis of 51 (1 µM).
To validate hit compounds further, we conducted an in vitro competitive CRBN binding assay
with a TR-FRET readout. The in vitro assay demonstrated that all five hit compounds bound
Page 9 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10
CRBN to a similar degree as lenalidomide (Figures 2B, Supplementary Figure S2). In addition,
we performed a cellular CRBN engagement assay. In brief, compounds are co-treated with the
BRD4 degrader dBET6 and cellular CRBN engagement is measured as the relative abundance of
BRD4BD2-GFP, as described previously.21 In the cellular assay, the hit compounds were also able
to engage CRBN to a similar extent as lenalidomide with the exception of 2 (Figures 2C,
Supplementary Figure S3); this may indicate that 2 has some difficulties with cell permeability
since the compound was able to bind CRBN in vitro.
We then examined via immunoblot whether these hit compounds induced the degradation of
previously identified targets of CRBN modulators. All five compounds induced some degradation
of GSPT1 in MM1.S cells after 4 h of treatment, with little to no detectable activity against IKZF1,
IKZF3, and CK1a (Figure 2D). Co-treatment with the proteasome inhibitor carfilzomib
demonstrated that the observed GSPT1 degradation for all five compounds was proteasome
mediated, while co-treatment with the neddylation inhibitor MLN4924 confirmed that the GSPT1
degradation was occurring via recruitment of CRL4CRBN (Supplementary Figure S4).
In order to characterize the selectivity profile of the hit compounds further and examine whether
they induce degradation of any additional proteins, we used quantitative proteomics with
compounds 29, 2, and 51; these compounds were selected due to their low degradative activity of
known CRBN modulator targets in order to identify unexpected degraded proteins, if any. In brief,
protein abundance was measured in multiplexed mass spectrometry-based proteomics using
tandem mass tag (TMT) isobaric labels as described previously10,22 after 6 h treatment in MM1.S
cells with 0.1 µM of CC-885, 1 µM of 29, 1 µM of 2, 1 µM of 51, or vehicle control. This
demonstrated that while CC-885 induced the downregulation of many proteins in MM1.S cells, 29
selectively induced the degradation of GSPT1, with no other statistically significant
Page 10 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11
downregulated targets after triplicate analysis (Figures 3A and 3B). Singlicate analysis of
expression proteomics with 2 (Figure 3C) and 51 (Figure 3D) showed similarly selective
degradation of GSPT1, with GSPT2, a close homolog of GSPT1,23 being the only other
downregulated target observed after treatment with 51. A single unique peptide of GSPT2 was
quantified and measured as downregulated for 2 and 29, but the resulting data was filtered to only
include proteins that had a minimum of three unique peptides in order to reduce false positives.
Figure 4. Molecular modeling of 26 identifies that the nitrogens in the pyrimidine ring are critical for
GSPT1 degradation. (A) CC-885 (gray) bound to CRBN (green) and GSPT1 (cyan) in a ternary complex
(PDB: 5HXB). (B) Docking of 26 (yellow) into PDB: 5HXB. (C) Structures of 26 and its analog 52, with
Page 11 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
12
the N-1 replaced with carbon. (D) Antiproliferative IC50 curves ± SD after 48 h treatments (three biological
replicates; Graphpad Prism 8 software). (E) Immunoblot after 4 h treatments in MM1.S cells. Vinculin
representative of 4 blots. Quantification shown as percentage of DMSO control normalized to vinculin.
To rationalize how our hit compounds might induce the binding of CRBN and GSPT1, all five
compounds were docked into the ternary complex model of CC-885 with CRBN and GSPT1
(PDB: 5HXB) using InducedFit protocol (Schrodinger suite release 2019-2). The binding mode of
CC-885 is shown in gray in Figure 4A and docking of 26 is shown in yellow in Figure 4B; all five
hit compounds showed similar binding modes as 26 (data not shown). Overall, 26 occupies the
same binding cavity formed at the interface between GSPT1 (cyan) and CRBN (green), and has a
very similar shape compared to CC-885. Besides forming the same interactions via the IMiD
portion of the molecule, both CC-885 and 26 form a hydrogen bond with His353 of CRBN.
However, we observed that 26 forms a hydrogen bond with Lys628 of GSPT1, which is not seen
with CC-885. In addition, the central pyrimidine ring of 26 was observed to retain a minimal twist
in the tail phenyl group when compared to the CC-885 phenyl group. Thus, the nitrogen of the
pyrimidine ring appears to play a critical role in GSPT1 binding. Therefore, we hypothesized that
if we replaced the N-1 with a carbon, it would disrupt the hydrogen bond with Lys628 and force
the terminal phenyl group to adopt a twisted conformation. Both effects together should have
detrimental consequences on the recruitment of GSPT1. To test this hypothesis, we synthesized
52 (Figure 4C).
Direct comparison of 26 and 52 demonstrated that the replacement of N-1 with carbon resulted
in a loss of CRBN-dependent antiproliferative activity in MM1.S cells, despite 52 retaining its
ability to bind CRBN (Figures 4D, Supplementary Figure S5). Additionally, examination by
immunoblot showed that 52 does not induce degradation of GSPT1 to the same extent as 26 (Figure
Page 12 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
13
4E). Together this indicates that the nitrogens in the pyrimidine ring of our hit compound are
essential for GSPT1 degradation, and likely essential for the recruitment of GSPT1 to the CRBN
E3 ubiquitin ligase complex. Furthermore, it is possible that an equivalent hydrogen bond
interaction cannot be made with zinc finger proteins, accounting for the observed selectivity
profile.
CONCLUSION
We have developed a prototype focused combinatorial library strategy that would be suitable for
building collections of imide-based compounds. Screening for CRBN-dependent antiproliferative
effects led to the identification of CRBN modulators that can induce the selective degradation of
GSPT1. In contrast to CC-885, which induces degradation of GSPT1, IKZF1/3 and a large number
of other proteins,12,24,25 our tool compounds are highly selective GSPT1/2 degraders with little to
no activity on IKZF1/3 and no observable off-target activity in global proteomics. This is
confirmed by our selective tool compounds exhibiting antiproliferative activity that is strictly
dependent on the expression of CRBN, while CC-885 retains antiproliferative activity with
unspecific toxicity in a CRBN-/- cell line (Figure 4D). The use of MM1.S cells likely biased our
results towards the identification of compounds that degrade factors such as IKZF1 and GSPT1,
which are known dependencies in these cells. Further exploration of our library with additional
cell lines may therefore reveal new molecular glues and their targets.
Taken together, we have successfully identified novel CRBN modulators with selective activity
towards GSPT1 and have identified a potential structural determinant for this selectivity. Due to
its potency and selectivity for GSPT1, compound 26 is a superior tool to CC-885 for exploring the
therapeutic potential of GSPT1 degradation and may provide additional opportunities for
Page 13 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
14
therapeutically targeting GSPT1, where a degradation-based strategy has already shown potential
in the treatment of acute myeloid leukemia (AML).26–29
METHODS
Cell Culture. MM1.S WT and MM1.S CRBN-/- cells were generously provided by James
Bradner (DFCI, Boston, MA). MM1.S cell lines were cultured in RPMI-1640 media containing L-
glutamine, supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
HEK293T cells were cultured om DMEM media containing L-glutamine, supplemented with 10%
FBS and 1% penicillin/streptomycin. Mycoplasma testing was performed on a monthly basis and
all lines were negative.
Cell Viability Assays. Cell viability was evaluated using the CellTiter-Glo Luminescent Cell
Viability Assay (Promega) following the manufacturer’s standards.
Immunoblotting. Cells were washed with PBS before being lysed with Cell Lysis Buffer (Cell
Signaling) supplemented with protease and phosphatase inhibitor cocktails (Roche) at 4°C for 15
minutes. The cell lysate vortexed before being centrifuged at 14,000 x g for 20 min at 4°C. Protein
in cell lysate was quantified by BCA assay (Pierce). Primary antibodies used in this study include
β-Actin (Cell Signaling Technology, 3700s), CK1a (Abcam, ab206652), CRBN (Novus
Biologicals, NBP1-91810), eRF3/GSPT1 (Abcam, ab49878), IKZF1 (Cell Signaling Technology,
5443S), IKZF3 (Cell Signaling Technology, 15103S), and vinculin (Abcam, ab130007). Blot
quantification was performed using Image Studio 4.0 software, normalizing to loading controls.
Purification of biotinylated DDB1∆B-CRBN. Human DDB1∆B and human CRBN were
cloned in pAC-derived vectors30 and recombinant proteins were expressed as N-terminal
His6 (DDB1ΔB) or StrepII-Avi (CRBN) fusions in Trichoplusia ni High-Five insect cells using
Page 14 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15
the baculovirus expression system (Invitrogen). For purification, cells were resuspended in buffer
containing 50 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) pH 8.0, 200 mM
NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1x protease inhibitor cocktail (2 μg/ml Aprotinin, 10μM Bestatin, 2μM E-64, 10μM
Leupeptin, 1μM Pepstatin A and 10μM 1,10 - Phenanthrolin and 1μM Phosphoramidon) and lysed
by sonication. Following ultracentrifugation, the soluble fraction was passed over Strep-Tactin XT
(IBA, 2-4030-025) resin and eluted with wash buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 1
mM TCEP) supplemented with 50 mM biotin (MedChemExpress, HY-B0511). The affinity-
purified protein was subjected to ion exchange chromatography (Poros 50HQ) followed by size
exclusion chromatography (16/60 S200, GE) in 50 mM HEPES pH 7.4, 200 mM NaCl and 1 mM
TCEP. Biotinylation of was performed as previously described.31 The protein-containing fractions
were concentrated using ultrafiltration (Millipore) and flash frozen in liquid nitrogen at 40-120
μM concentration and stored at -80°C.
In vitro CRBN Binding Assay. Competitive binding to DDB1∆B-CRBN1 was measured in
vitro by titrating compounds into 10 nM Lenalidomide-BodipyFL, 100 nM biotinylated DDB1∆B-
CRBN, 2 nMTerbium-Streptavidin in a buffer containing 50 mM Tris pH 7.5, 200 mM NaCl, 0.1%
Pluronic F-68 solution (Sigma). Titrations of compounds were performed using d300 dispenser
(HP) and final DMSO concentration normalized to 1%. All biochemical assays were performed in
384-well low volume plates (Corning, 4514) using 15 μL assay volume. Substrate recruitment was
measured using Pherastar (BMG) plate reader with excitation at 337 nm using 520/490 nm filter
for signal detection. The TR-FRET signal was calculated as ratio of 520/490 emission. The IC50
values were calculated using a nonlinear fit variable slope model (GraphPad Prism Software). Data
are presented as means normalized to DMSO ± standard deviation of n = 3 technical replicates.
Page 15 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16
Cellular CRBN engagement assay. HEK293T cells stably expressing BRD4BD2-eGFP protein
fusion with mCherry reporter were seeded at a density of 1000-4000 cells/well in a 384-well plate
(Corning, 3764). BRD4BD2-GFP reporter cells were treated with increasing concentrations of
lenalidomide or indicated compounds for 5 hrs in the presence of 100 nM dBET6. Relative
abundance of BRD4BD2-GFP was measured by Laser Scanning Cytometry (Acumen). Green
fluorescent signal (excitation laser: 488 nm; filter: 500-530 nm) and red florescent signal
(excitation laser: 561 nm; filter: 575-640 nm) were individually measured and exported for
analysis. Data analysis was performed using Cell Profiler,32 as previously described.21 The
compound concentrations which resulted in 50% degradation of BRD4BD2-GFP (DC50) were
calculated using a nonlinear fit variable slope model (GraphPad Prism Software). Data are
represented as means ± s.d of three replicates (n = 3).
Sample preparation TMT LC-MS3 mass spectrometry. MM1.S cells were treated with
DMSO or 1 µM of compound ZXH-1-167 (29) in biological triplicates, 0.1 µM of DGY-4-189
(CC-885) in biological duplicates, and 1 µM of ZXH-1-084 (2) and 1 µM of ZXH-1-164 (51) in
biological singlicate for 6 h. Cells were harvested by centrifugation and prepared for mass
spectrometry as described previously.33,34 Data was collected as reported.33,34
LC-MS data analysis. Data was analyzed using Proteome Discoverer 2.2 (Thermo Fisher
Scientific) as described.33,34 Reporter ion intensities were normalized and scaled using in-house
scripts in the R framework.35 Statistical analysis was carried out using the limma package within
the R framework.36
Page 16 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17
ASSOCIATED CONTENT
Supporting Information
The Supporting Information (PDF) is available free of charge on the ACS Publications website.
Antiproliferative IC50 curves in MM1.S cells.
In vitro and cellular CRBN binding assay IC50s.
Immunoblots of proteasome inhibitor co-treatments.
Chemical synthesis experimental methods.
AUTHOR INFORMATION
Corresponding Author
* Correspondence: Nathanael_Gray@dfci.harvard.edu (N.S.G.).
Author Contributions
‡These authors (C.E.P. and G.D.) contributed equally.
Funding Sources
Funding for this work was received from the National Institutes of Health (NIH): Grant R01
CA214608 (E.S.F.) and 5 F31 CA210619-02 (C.E.P.).
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
We would like to thank M. Kostic for helpful feedback on the manuscript.
Page 17 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18
ABBREVIATIONS
AML, acute myeloid leukemia; CK1a, casein kinase 1A1; CRBN, cereblon; GSPT1, G1 to S
phase transition protein 1; IKZF1, Ikaros; IKZF3, Aiolos; IMiD, immunomodulatory drug.
REFERENCES
(1) Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H.
Identification of a Primary Target of Thalidomide Teratogenicity. Science 2010, 327 (5971), 1345–
1350. https://doi.org/10.1126/science.1177319.
(2) Bartlett, J. B.; Dredge, K.; Dalgleish, A. G. The Evolution of Thalidomide and Its IMiD
Derivatives as Anticancer Agents. Nat Rev Cancer 2004, 4 (4), nrc1323.
https://doi.org/10.1038/nrc1323.
(3) Rajkumar, S. V.; Hayman, S. R.; Lacy, M. Q.; Dispenzieri, A.; Geyer, S. M.; Kabat, B.;
Zeldenrust, S. R.; Kumar, S.; Greipp, P. R.; Fonseca, R.; Lust, J. A.; Russell, S. J.; Kyle, R. A.;
Witzig, T. E.; Gertz, M. A. Combination Therapy with Lenalidomide plus Dexamethasone
(Rev/Dex) for Newly Diagnosed Myeloma. Blood 2005, 106 (13), 4050.
https://doi.org/10.1182/blood-2005-07-2817.
(4) Lacy, M. Q.; Hayman, S. R.; Gertz, M. A.; Dispenzieri, A.; Buadi, F.; Kumar, S.; Greipp, P.
R.; Lust, J. A.; Russell, S. J.; Dingli, D.; Kyle, R. A.; Fonseca, R.; Bergsagel, P. L.; Roy, V.;
Mikhael, J. R.; Stewart, A. K.; Laumann, K.; Allred, J. B.; Mandrekar, S. J.; Rajkumar, S. V.
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple
Myeloma. J Clin Oncol 2009, 27 (30), 5008–5014. https://doi.org/10.1200/jco.2009.23.6802.
Page 18 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19
(5) Fischer, E. S.; Böhm, K.; Lydeard, J. R.; Yang, H.; Stadler, M. B.; Cavadini, S.; Nagel, J.;
Serluca, F.; Acker, V.; Lingaraju, G. M.; Tichkule, R. B.; Schebesta, M.; Forrester, W. C.; Schirle,
M.; Hassiepen, U.; Ottl, J.; Hild, M.; Beckwith, R. E. J.; Harper, J. W.; Jenkins, J. L.; Thomä, N.
H. Structure of the DDB1-CRBN E3 Ubiquitin Ligase in Complex with Thalidomide. Nature
2014, 512 (7512), 49 53. https://doi.org/10.1038/nature13527.
(6) Chamberlain, P. P.; Lopez-Girona, A.; Miller, K.; Carmel, G.; Pagarigan, B.; Chie-Leon, B.;
Rychak, E.; Corral, L. G.; Ren, Y. J.; Wang, M.; Riley, M.; Delker, S. L.; Ito, T.; Ando, H.; Mori,
T.; Hirano, Y.; Handa, H.; Hakoshima, T.; Daniel, T. O.; Cathers, B. E. Structure of the Human
Cereblon–DDB1–Lenalidomide Complex Reveals Basis for Responsiveness to Thalidomide
Analogs. Nat Struct Mol Biol 2014, 21 (9), 803–809. https://doi.org/10.1038/nsmb.2874.
(7) Lopez-Girona, A.; Mendy, D.; Ito, T.; Miller, K.; Gandhi, A. K.; Kang, J.; Karasawa, S.;
Carmel, G.; Jackson, P.; Abbasian, M.; Mahmoudi, A.; Cathers, B.; Rychak, E.; Gaidarova, S.;
Chen, R.; Schafer, P. H.; Handa, H.; Daniel, T. O.; Evans, J. F.; Chopra, R. Cereblon Is a Direct
Protein Target for Immunomodulatory and Antiproliferative Activities of Lenalidomide and
Pomalidomide. Leukemia 2012, 26 (11), 2326 2335. https://doi.org/10.1038/leu.2012.119.
(8) Lu, G.; Middleton, R. E.; Sun, H.; Naniong, M.; Ott, C. J.; Mitsiades, C. S.; Wong, K.-K.;
Bradner, J. E.; Kaelin, W. G. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent
Destruction of Ikaros Proteins. Science 2014, 343 (6168), 305–309.
https://doi.org/10.1126/science.1244917.
(9) Kronke, J.; Udeshi, N. D.; Narla, A.; Grauman, P.; Hurst, S. N.; McConkey, M.; Svinkina,
T.; heckl, D.; Comer, E.; Li, X.; Ciarlo, C.; Hartman, E.; Munshi, N.; Schenone, M.; Schreiber, S.
L.; Carr, S. A.; Ebert, B. L. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in
Page 19 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20
Multiple Myeloma Cells. Science 2014, 343 (6168), 301 305.
https://doi.org/10.1126/science.1244851.
(10) Donovan, K. A.; An, J.; Nowak, R. P.; Yuan, J. C.; Fink, E. C.; Berry, B. C.; Ebert, B. L.;
Fischer, E. S. Thalidomide Promotes Degradation of SALL4, a Transcription Factor Implicated in
Duane Radial Ray Syndrome. Elife 2018, 7, e38430. https://doi.org/10.7554/elife.38430.
(11) Petzold, G.; Fischer, E. S.; Thomä, N. H. Structural Basis of Lenalidomide-Induced CK1α
Degradation by the CRL4CRBN Ubiquitin Ligase. Nature 2016, 532 (7597), 127 130.
https://doi.org/10.1038/nature16979.
(12) Matyskiela, M. E.; Lu, G.; Ito, T.; Pagarigan, B.; Lu, C.-C.; Miller, K.; Fang, W.; Wang,
N.-Y.; Nguyen, D.; Houston, J.; Carmel, G.; Tran, T.; Riley, M.; Nosaka, L.; Lander, G. C.;
Gaidarova, S.; Xu, S.; Ruchelman, A. L.; Handa, H.; Carmichael, J.; Daniel, T. O.; Cathers, B. E.;
Lopez-Girona, A.; Chamberlain, P. P. A Novel Cereblon Modulator Recruits GSPT1 to the
CRL4CRBN Ubiquitin Ligase. Nature 2016, 535 (7611), 252–257.
https://doi.org/10.1038/nature18611.
(13) Krönke, J.; Fink, E. C.; Hollenbach, P. W.; MacBeth, K. J.; Hurst, S. N.; Udeshi, N. D.;
Chamberlain, P. P.; Mani, D. R.; Man, H.-W.; Gandhi, A. K.; Svinkina, T.; Schneider, R. K.;
McConkey, M.; Järås, M.; Griffiths, E.; Wetzler, M.; Bullinger, L.; Cathers, B. E.; Carr, S. A.;
Chopra, R.; Ebert, B. L. Lenalidomide Induces Ubiquitination and Degradation of CK1α in
Del(5q) MDS. Cell 2015, 523 (7559), 183 188. https://doi.org/10.1016/j.cell.2014.04.028.
(14) Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza, A.; Dhe-Paganon, S.;
Bradner, J. E. Phthalimide Conjugation as a Strategy for in Vivo Target Protein Degradation.
Science 2015, 348 (6241), 1376 1381. https://doi.org/10.1126/science.aab1433.
Page 20 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21
(15) Bondeson, D. P.; Mares, A.; Smith, I. E. D.; Ko, E.; Campos, S.; Miah, A. H.; Mulholland,
K. E.; Routly, N.; Buckley, D. L.; Gustafson, J. L.; Zinn, N.; Grandi, P.; Shimamura, S.;
Bergamini, G.; Faelth-Savitski, M.; Bantscheff, M.; Cox, C.; Gordon, D. A.; Willard, R. R.;
Flanagan, J. J.; Casillas, L. N.; Votta, B. J.; Besten, W. den; Famm, K.; Kruidenier, L.; Carter, P.
S.; Harling, J. D.; Churcher, I.; Crews, C. M. Catalytic in Vivo Protein Knockdown by Small-
Molecule PROTACs. Behav Brain Res 2015, 11 (8), 611 617. https://doi.org/10.1016/s0166-
4328(01)00297-2.
(16) Paiva, S.-L.; Crews, C. M. Targeted Protein Degradation: Elements of PROTAC Design.
Curr Opin Chem Biol 2019, 50, 111–119. https://doi.org/10.1016/j.cbpa.2019.02.022.
(17) Matyskiela, M. E.; Zhang, W.; Man, H.-W.; Muller, G.; Khambatta, G.; Baculi, F.;
Hickman, M.; LeBrun, L.; Pagarigan, B.; Carmel, G.; Lu, C.-C.; Lu, G.; Riley, M.; Satoh, Y.;
Schafer, P.; Daniel, T. O.; Carmichael, J.; Cathers, B. E.; Chamberlain, P. P. A Cereblon Modulator
(CC-220) with Improved Degradation of Ikaros and Aiolos. J Med Chem 2017, 61 (2).
https://doi.org/10.1021/acs.jmedchem.6b01921.
(18) Chamberlain, P. P.; Cathers, B. E. Cereblon Modulators: Low Molecular Weight Inducers
of Protein Degradation. Drug Discov Today Technologies 2019, 31 (Curr Med Chem 25 31 2018).
https://doi.org/10.1016/j.ddtec.2019.02.004.
(19) Chamberlain, P. P.; Hamann, L. G. Development of Targeted Protein Degradation
Therapeutics. Nat Chem Biol 2019, 15 (10), 937–944. https://doi.org/10.1038/s41589-019-0362-
y.
(20) Mullard, A. First Targeted Protein Degrader Hits the Clinic. Nat Rev Drug Discov 2019.
https://doi.org/10.1038/d41573-019-00043-6.
Page 21 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22
(21) Gasic, I.; Groendyke, B. J.; Nowak, R. P.; Yuan, J. C.; Kalabathula, J.; Fischer, E. S.; Gray,
N. S.; Mitchison, T. J. Tubulin Resists Degradation by Cereblon-Recruiting PROTACs. Cells
2020, 9 (5), 1083. https://doi.org/10.3390/cells9051083.
(22) McAlister, G. C.; Nusinow, D. P.; Jedrychowski, M. P.; Wühr, M.; Huttlin, E. L.; Erickson,
B. K.; Rad, R.; Haas, W.; Gygi, S. P. MultiNotch MS3 Enables Accurate, Sensitive, and
Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes. Anal Chem
2014, 86 (14), 7150–7158. https://doi.org/10.1021/ac502040v.
(23) Goff, C. L.; Zemlyanko, O.; Moskalenko, S.; Berkova, N.; Inge-Vechtomov, S.; Philippe,
M.; Zhouravleva, G. Mouse GSPT2, but Not GSPT1, Can Substitute for Yeast ERF3 in Vivo.
Genes Cells 2002, 7 (10), 1043–1057. https://doi.org/10.1046/j.1365-2443.2002.00585.x.
(24) Hansen, J. D.; Condroski, K. R.; Correa, M.; Muller, G. W.; Man, H.-W.; Ruchelman, A.
L.; Zhang, W.; Vocanson, F.; Crea, T.; Liu, W.; Lu, G.; Baculi, F.; LeBrun, L.; Mahmoudi, A.;
Carmel, G.; Hickman, M. G.; Lu, C.-C. Protein Degradation via CRL4CRBN Ubiquitin Ligase:
Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote
Degradation of Aiolos and/or GSPT1. J Med Chem 2017, 61 (2).
https://doi.org/10.1021/acs.jmedchem.6b01911.
(25) Hao, B.; Li, X.; Jia, X.; Wang, Y.; Zhai, L.; Li, D.; Liu, J.; Zhang, D.; Chen, Y.; Xu, Y.;
Lee, S.; Xu, G.; Chen, X.; Dang, Y.; Liu, B.; Tan, M. The Novel Cereblon Modulator CC-885
Inhibits Mitophagy via Selective Degradation of BNIP3L. Acta Pharmacol Sin 2020, 1–9.
https://doi.org/10.1038/s41401-020-0367-9.
(26) Jin, L.; Mbong, N.; Ng, S. W. K.; Wang, J. C. Y.; Minden, M. D.; Fan, J.; Pierce, D. W.;
Pourdehnad, M.; Dick, J. E. A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid
Page 22 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23
Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1. Blood 2019,
134 (Supplement_1), 3940–3940. https://doi.org/10.1182/blood-2019-128450.
(27) Lopez-Girona, A.; Lu, G.; Rychak, E.; Mendy, D.; Lu, C.-C.; Rappley, I.; Fontanillo, C.;
Cathers, B. E.; Daniel, T. O.; Hansen, J. CC-90009, a Novel Cereblon E3 Ligase Modulator,
Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid
Leukemia (AML). Blood 2019, 134 (Supplement_1), 2703–2703. https://doi.org/10.1182/blood-
2019-127892.
(28) Lu, G.; Surka, C.; Lu, C.-C.; Jang, I. S.; Wang, K.; Rolfe, M. Elucidating the Mechanism
of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide
CRISPR Screen. Blood 2019, 134 (Supplement_1), 405–405. https://doi.org/10.1182/blood-2019-
125492.
(29) Uy, G. L.; Minden, M. D.; Montesinos, P.; DeAngelo, D. J.; Altman, J. K.; Koprivnikar, J.;
Vyas, P.; Fløisand, Y.; Vidriales, M. B.; Gjertsen, B. T.; Esteve, J.; Buchholz, T. J.; Couto, S.;
Fan, J.; Hanna, B.; Li, L.; Pierce, D. W.; Hege, K.; Pourdehnad, M.; Zeidan, A. M. Clinical
Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a
Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First
Results from a Phase I Dose-Finding Study. Blood 2019, 134 (Supplement_1), 232–232.
https://doi.org/10.1182/blood-2019-123966.
(30) Abdulrahman, W.; Uhring, M.; Kolb-Cheynel, I.; Garnier, J.-M.; Moras, D.; Rochel, N.;
Busso, D.; Poterszman, A. A Set of Baculovirus Transfer Vectors for Screening of Affinity Tags
and Parallel Expression Strategies. Anal Biochem 2009, 385 (2), 383–385.
https://doi.org/10.1016/j.ab.2008.10.044.
Page 23 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24
(31) Cavadini, S.; Fischer, E. S.; Bunker, R. D.; Potenza, A.; Lingaraju, G. M.; Goldie, K. N.;
Mohamed, W. I.; Faty, M.; Petzold, G.; Beckwith, R. E. J.; Tichkule, R. B.; Hassiepen, U.;
Abdulrahman, W.; Pantelic, R. S.; Matsumoto, S.; Sugasawa, K.; Stahlberg, H.; Thomä, N. H.
Cullin–RING Ubiquitin E3 Ligase Regulation by the COP9 Signalosome. Nature 2016, 531
(7596), 598–603. https://doi.org/10.1038/nature17416.
(32) Carpenter, A. E.; Jones, T. R.; Lamprecht, M. R.; Clarke, C.; Kang, I. H.; Friman, O.;
Guertin, D. A.; Chang, J. H.; Lindquist, R. A.; Moffat, J.; Golland, P.; Sabatini, D. M. CellProfiler:
Image Analysis Software for Identifying and Quantifying Cell Phenotypes. Genome Biol 2006, 7
(10), R100. https://doi.org/10.1186/gb-2006-7-10-r100.
(33) Li, Z.; Pinch, B. J.; Olson, C. M.; Donovan, K. A.; Nowak, R. P.; Mills, C. E.; Scott, D. A.;
Doctor, Z. M.; Eleuteri, N. A.; Chung, M.; Sorger, P. K.; Fischer, E. S.; Gray, N. S. Development
and Characterization of a Wee1 Kinase Degrader. Cell Chem Biol 2019.
https://doi.org/10.1016/j.chembiol.2019.10.013.
(34) Brand, M.; Jiang, B.; Bauer, S.; Donovan, K. A.; Liang, Y.; Wang, E. S.; Nowak, R. P.;
Yuan, J. C.; Zhang, T.; Kwiatkowski, N.; Müller, A. C.; Fischer, E. S.; Gray, N. S.; Winter, G. E.
Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. Cell Chem
Biol 2019, 26 (2), 300-306.e9. https://doi.org/10.1016/j.chembiol.2018.11.006.
(35) Team, R. D. C. R: A Language and Environment for Statistical Computing http://www.R-
project.org/.
(36) Ritchie, M. E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C. W.; Shi, W.; Smyth, G. K. Limma
Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. Nucleic
Acids Res 2015, 43 (7), e47 e47. https://doi.org/10.1093/nar/gkv007.
Page 24 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25
For Table of Contents Only
Page 25 of 25
ACS Paragon Plus Environment
ACS Chemical Biology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
